Xencor (NASDAQ:XNCR) Stock Price Up 7.9% - What's Next?

Key Points

• Xencor shares rose 7.9% in Friday trading, reaching as high as $15.97 before last trading at $16.14, though volume was well below average.
• Analysts remain mixed on the stock: recent updates included target-price changes and rating shifts, but the overall consensus is still a Moderate Buy with an average target price of $24.25.
• The company’s latest earnings were weak, with a larger-than-expected loss and revenue far below estimates, while analysts expect Xencor to post a full-year EPS of -3.88.

Xencor, Inc. (NASDAQ:XNCR - Get Free Report)'s share price was up 7.9% during mid-day trading on Friday . The stock traded as high as $15.97 and last traded at $16.1360. Approximately 127,126 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 796,496 shares. The stock had previously closed at $14.95.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on XNCR shares. JPMorgan Chase & Co. upped their target price on Xencor from $13.00 to $14.00 and gave the company a "neutral" rating in a research note on Monday, May 11th. Wall Street Zen lowered shares of Xencor from a "hold" rating to a "strong sell" rating in a report on Saturday, May 9th. Zacks Research raised Xencor from a "strong sell" rating to a "hold" rating in a research note on Monday, July 6th. Weiss Ratings reissued a "sell (d-)" rating on shares of Xencor in a research note on Wednesday, June 24th. Finally, Truist Financial dropped their price target on shares of Xencor from $29.00 to $27.00 and set a "buy" rating for the company in a research note on Tuesday, July 7th. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $24.25.

Xencor Price Performance

The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -7.06 and a beta of 0.86. The firm has a 50-day moving average price of $13.12 and a two-hundred day moving average price of $12.76.

Xencor (NASDAQ:XNCR - Get Free Report) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.96). The business had revenue of $4.52 million during the quarter, compared to the consensus estimate of $27.86 million. Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The firm's revenue for the quarter was down 86.2% on a year-over-year basis. During the same period last year, the business posted ($0.66) EPS. On average, equities analysts predict that Xencor, Inc. will post -3.88 EPS for the current year.

Hedge Funds Weigh In On Xencor

A number of institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC raised its position in shares of Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company's stock valued at $44,000 after purchasing an additional 3,018 shares during the period. E Fund Management Co. Ltd. acquired a new stake in Xencor in the second quarter valued at about $79,000. Wealth Enhancement Advisory Services LLC acquired a new position in Xencor during the 4th quarter worth approximately $81,000. iSAM Funds UK Ltd acquired a new stake in shares of Xencor during the 2nd quarter valued at $122,000. Finally, Prelude Capital Management LLC acquired a new stake in Xencor in the third quarter valued at $139,000.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.